Journal: Oncology and therapy
The publication reviews therapeutic advances in metastatic triple-negative breast cancer (TNBC), highlighting the limited efficacy of chemotherapy, immune checkpoint inhibitors, and PARP inhibitors.
Antibody-drug conjugates (ADCs) have emerged as a promising class, with sacituzumab govitecan, SKB264, and datopotamab deruxtecan demonstrating improved progression-free survival and high objective response rates.
In HER2-low TNBC, agents like trastuzumab deruxtecan have extended overall survival, while other ADCs targeting HER3, Nectin-4, LIV-1, and folate receptor α show variable response rates.
Resistance mechanisms include antigen loss and cellular processing defects.
Ongoing research focuses on:
- Bispecific ADCs
- Optimization of linkers
- Combination therapies
- Novel targets such as EGFR and folate receptor α
- Multimodal immunovascular approaches to enhance clinical outcomes